Friday 6 November 2026 Export CLDX’s income statement to Excel — free account

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.

Revenue: −96.8%
EPS: −10.6%
Free cash flow: −35.5%

Quarter to June 2026, against a year earlier

29.52 1.25 +4.42%

Follow CLDX

Alert me

Market cap: $2.2B
P/E: 0.0×
Fwd P/E: −7.2×
Dividend yield: —
F-score: 2/9
Altman Z: 14.41
Beneish M: 6.76
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 0.12

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 2.47%

Capital & Financial Ratios $m

Size

Market Cap 2,220.00

Revenue ttm 0.89

Net income ttm (300.55)

Free cash flow ttm (242.10)

Net debt Q (716.36)

Valuation

P/E 0.00

Forward P/E (7.17)

Price / sales 2,497.55

Forward P/S Powerpack

Price / FCF 0.00

Price / book 3.10

Financial health

Current ratio Q 11.82

Debt / equity Q 0.00

Interest coverage Q 0.00

Growth

Revenue growth Q −96.83%

Operating income growth Q −26.26%

EPS, this year −5.63%

EPS, next year A −1.63%

Revenue, next year A +19.74%

EPS, past 5 yrs —

EPS, next 5 yrs A +5.17%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 96.81%

10-year low 10-year high

P/B against its own 10 years 62.27%

10-year low 10-year high

EV/Sales against its own 10 years 95.95%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	424	725	519	718
Receivables	3	1	2	0
Inventory	—	—	—	—
Other	—	—	—	—
	432	747	535	725

	2023	2024	2025	Q'26
Payables	3	3	1	15
ST’ Debt	4	1	1	1
Other	—	—	—	—
	31	40	51	61

Compound Annual Growth %

	10y	5y	3y
Sales	(11.89%)	(26.93%)	(13.13%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	6.15%	20.29%	17.35%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −1.04 Actual −0.94

−1.27 −1.16 −1.05 −0.94 −0.83

Q3 FY25 Miss −0.13

Q4 FY25 Miss −0.22

Q1 FY26 Miss −0.08

Q2 FY26 Beat +0.10

Q3 FY26 — Nov 9

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.88	−1.01	Miss by 0.13
Q4 FY25	−1.00	−1.22	Miss by 0.22
Q1 FY26	−1.10	−1.18	Miss by 0.08
Q2 FY26	−1.04	−0.94	Beat by 0.10
Q3 FY26	−1.02	—	Reports 9 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.18)	(0.94)	—	—	—
’25	(0.81)	(0.85)	(1.01)	(1.22)	(3.90)
’24	(0.56)	(0.54)	(0.64)	(0.71)	(2.45)
’23	(0.62)	(0.65)	(0.81)	(0.83)	(2.92)
’22	(0.49)	(0.77)	(0.57)	(0.56)	(2.40)
’21	(0.42)	(0.34)	(0.45)	(0.43)	(1.64)
’20	(0.73)	(0.50)	(0.36)	(0.55)	(2.02)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	1	1	—	0	2
’24	0	2	3	1	7
’23	1	0	2	4	7
’22	0	0	0	2	2
’21	1	3	0	0	5
’20	3	0	1	4	7

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(66)	(57)	—	—	—
’25	(54)	(44)	(49)	(64)	(211)
’24	(41)	(29)	(55)	(32)	(158)
’23	(29)	(27)	(19)	(33)	(107)
’22	(25)	(22)	(35)	(22)	(104)
’21	(18)	(12)	(16)	(15)	(61)
’20	(12)	(11)	(12)	(5)	(40)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(67)	(61)	—	—	—
’25	(55)	(45)	(49)	(65)	(214)
’24	(41)	(30)	(56)	(33)	(160)
’23	(29)	(28)	(19)	(33)	(109)
’22	(25)	(23)	(35)	(22)	(105)
’21	(19)	(12)	(17)	(15)	(62)
’20	(12)	(12)	(12)	(5)	(42)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	7	13	10	4	7	5	2	7	7	2	1		(15.2%)	2	9	123	+329.7%
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		0.0 pt	Powerpack Celldex Therapeutics, Inc.’s next three years, line by line Analysts expect revenue to grow 329.7% a year to 2028 — faster than the −15.2% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(129)	(117)	(152)	(51)	(61)	(71)	(112)	(141)	(158)	(259)	(301)		+8.1%
	EBT margin, %	(1,894.05)	(920.61)	(1,593.09)	(1,423.96)	(821.61)	(1,520.92)	(4,765.59)	(2,054.76)	(2,248.76)	(16,748.03)	(33,883.77)		(14,854.0) pt
	Net income	(129)	(93)	(151)	(51)	(60)	(71)	(112)	(141)	(158)	(259)	(301)		+8.1%
Per share, $
Per share, $	Revenue	1.00	1.49	0.91	0.25	0.25	0.11	0.05	0.14	0.11	0.02	0.01		(34.2%)
	Earnings	(19.04)	(10.79)	(14.48)	(3.51)	(2.02)	(1.64)	(2.40)	(2.92)	(2.45)	(3.90)	(4.35)		(16.2%)
	Cash flow	(16.70)	(11.66)	(7.20)	(3.20)	(1.36)	(1.42)	(2.21)	(2.21)	(2.45)	(3.18)	(3.03)		(16.8%)
	Capex	(0.41)	(0.21)	(0.05)	(0.05)	(0.05)	(0.03)	(0.04)	(0.04)	(0.03)	(0.04)	(0.08)		(22.5%)
	Free cash flow	(17.11)	(11.87)	(7.25)	(3.25)	(1.41)	(1.45)	(2.25)	(2.25)	(2.48)	(3.22)	(3.11)		(16.9%)
	Book value	39.21	27.58	11.88	6.48	7.06	9.78	6.96	8.86	11.60	7.94	9.18		(16.3%)
	Shares, m	7	9	10	15	30	43	47	48	64	66	69		+28.9%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	54.01	29.46	3.25	9.05	70.00	356.16	863.16	284.44	231.80	663.24	2,497.55		256.5
	P/B	1.38	1.59	0.25	0.34	2.48	3.95	6.24	4.56	2.18	3.42	3.10		2.6
	EV/Sales	26.76	19.03	(6.13)	(7.94)	44.26	269.04	734.75	223.67	128.81	473.52	1,691.39		190.6
	EV/FCF	(1.57)	(2.38)	0.77	0.60	(7.84)	(20.14)	(16.42)	(14.11)	(5.66)	(6.03)	(6.20)		(7.3)
Cash, $m
Cash, $m	Operating cash flow	(113)	(100)	(75)	(46)	(40)	(61)	(104)	(107)	(158)	(211)	(236)		+7.2%
	Capex	(3)	(2)	0	(1)	(1)	(1)	(2)	(2)	(2)	(3)	(7)		(0.2%)
	Free cash flow	(116)	(102)	(76)	(47)	(42)	(62)	(105)	(109)	(160)	(214)	(242)		+7.0%
Balance, $m
Balance, $m	Working capital	160	117	86	55	184	394	299	401	708	484	664		+13.1%
	Net debt	(185)	(133)	(89)	(61)	(191)	(405)	(304)	(420)	(724)	(517)	(716)		+12.1%
	Shareholders’ equity	265	236	124	94	209	419	326	429	747	527	715		+7.9%
Returns, %
Returns, %	ROA	(35.66)	(26.62)	(64.14)	(36.51)	(33.32)	(20.72)	(28.17)	(34.56)	(25.10)	(37.63)	(40.76)		(2.0) pt
	ROIC	(103.22)	(73.38)	(282.87)	(103.29)	(215.01)	(312.08)	(317.32)	(1,010.24)	(537.91)	(1,828.59)	0.00		(1,725.4) pt
	ROE	(46.27)	(37.08)	(83.89)	(46.66)	(39.41)	(22.43)	(30.13)	(37.45)	(26.84)	(40.62)	(43.88)		+5.6 pt
People
People	Employees	210	197	137	130	125	134	148	160	186	198	—		(0.7%)
	Revenue/emp, $m	0.03	0.06	0.07	0.03	0.06	0.03	0.02	0.04	0.04	0.01	—		(14.6%)

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADMA ADMA Biologics Inc	$3.0B	16.7×	14.0×	+5.12% (above 0%: growing)	+46.67% (above 0%: growing)	+1,709.49% (above 0%: growing)	70.81%	48.02%	Compare
VCEL Vericel Corporation	$2.7B	77.8×	72.9×	+26.47% (above 0%: growing)	+180.00% (above 0%: growing)	−19.39% (below 0%: shrinking)	73.34%	14.27%	Compare
PHVS Pharvaris N.V.	$2.3B	— (loss-making)	—	—	n/m	−17.31% (below 0%: shrinking)	0.00%	0.00%	Compare
PVLA Palvella Therapeutics, Inc.	$2.3B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
CLDX Celldex Therapeutics, Inc.	$2.2B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−35.45% (below 0%: shrinking)	100.00%	(366,468.18%)
VERA Vera Therapeutics, Inc.	$2.2B	— (loss-making)	—	—	n/m	−82.47% (below 0%: shrinking)	0.00%	0.00%	Compare
AUPH Aurinia Pharmaceuticals Inc	$2.2B	6.8×	17.6×	+13.93% (above 0%: growing)	0.00%	+4.41% (above 0%: growing)	90.08%	40.74%	Compare
IMNM Immunome, Inc.	$2.1B	— (loss-making)	— (loss-making)	+69.84% (above 0%: growing)	n/m	−26.96% (below 0%: shrinking)	100.00%	0.00%	Compare
BHVN Biohaven Ltd.	$2.1B	— (loss-making)	— (loss-making)	+131.43% (above 0%: growing)	n/m	+26.55% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$2.2B	16.7×	17.6×	+20.20%	+46.67%	−18.35%	72.08%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 29 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	5.37m	4.83m	155.00
2024	9.23m	75.80k	144.00
2023	8.36m	3.74m	226.00
2022	5.40m	10.10m	254.00
2021	6.05m	13.90m	221.00

Ownership

Directors and executive officers, together 5.20%

Wellington Management Group LLP 10.30%

Kynam Capital Management, LP 8.30%

FMR LLC 6.20%

BlackRock Inc. 6.10%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Celldex Therapeutics, Inc. (CLDX) Latest News

5 Nov

Impact 4 · 4:01 PM · GlobeNewswire

Celldex Reports Third Quarter Financial Results and Provides Corporate Update

16 Oct

Impact 3 · 8:15 PM · Simply Wall St.

Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation

23 Sep

Impact 4 · 8:41 AM · Insider Monkey

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

22 Sep

Impact 4 · 12:02 PM · MarketBeat

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses

Impact 4 · 9:40 AM · InvestorsHub

Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials

Impact 4 · 7:31 AM · MT Newswires

Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials

Impact 4 · 6:58 AM · GlobeNewswire

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

Impact 3 · 1:10 PM · Stocktwits

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

9 Aug

Impact 4 · 2:13 AM

Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results

Impact 3 · 12:24 AM

Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?

8 Aug

Impact 4 · 5:15 PM

What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?

22 Jul

Impact 4 · 6:02 AM · MarketBeat

Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss

Impact 4 · 5:33 AM · biopharmadive.com

Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study

21 Jul

Impact 4 · 4:01 PM

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Impact 3 · 6:52 PM · Stocktwits

CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?

14 Jun

Impact 4 · 10:21 AM

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Impact 4 · 5:15 AM

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

7 May

Impact 3 · 4:01 PM · GlobeNewswire

Celldex Reports First Quarter Financial Results and Provides Corporate Update

4 May

Impact 3 · 9:55 AM · Zacks

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?

15 Apr

Impact 4 · 3:33 AM · MarketBeat

Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment

6 Apr

Impact 4 · 10:53 AM · GlobeNewswire

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2 Apr

Impact 4 · 12:26 PM · GuruFocus.com

Celldex shares plunge after dumping $300 million stock deal

Impact 4 · 7:18 AM · Simply Wall St.

Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX?

1 Apr

Impact 4 · 9:48 PM · GlobeNewswire

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Impact 4 · 4:01 PM · GlobeNewswire

Celldex Announces Proposed Public Offering of Common Stock

27 Mar

Impact 4 · 10:30 AM · GlobeNewswire

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

14 Mar

Impact 4 · 6:07 AM · MarketBeat

Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts

8 Mar

Impact 5 · 11:46 AM · MarketBeat

Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference

1 Mar

Impact 4 · 9:45 AM · GlobeNewswire

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

27 Feb

Impact 3 · 9:13 PM · Simply Wall St.

Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Celldex Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 29 April 2026

Chief executive’s pay

Ownership

Celldex Therapeutics, Inc. (CLDX) Latest News

5 Nov

16 Oct

23 Sep

22 Sep

9 Aug

8 Aug

22 Jul

21 Jul

14 Jun

7 May

4 May

15 Apr

6 Apr

2 Apr

1 Apr

27 Mar

14 Mar

8 Mar

1 Mar

27 Feb

CLDX metrics, ten years each

Stockrow Weekly